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Abstract: Pancreatic adenocarcinoma has a horrible prognosis, which is partly due to difficulties in
diagnosing the disease in an early stage. Additional blood-born biomarkers for pancreatic adeno-
carcinoma are needed. Epigenetic modifications, as changes in DNA methylation, is a fundamental
part of carcinogenesis. The aim of this paper is to do an update on cell-free DNA methylation as
blood-based biomarkers for pancreatic adenocarcinoma. The current literature including our studies
clearly indicates that cell-free DNA methylation has the potential as blood-based diagnostic and
prognostic biomarkers for pancreatic adenocarcinoma. However, still no clinical applicable biomarker
for pancreatic adenocarcinoma based on DNA methylation do exist. Further well-designed validation
studies are needed.
Keywords: pancreatic cancer; pancreatic ductal adenocarcinoma; epigenetic; DNA methylation;
diagnostic biomarker; prognostic biomarker; cell-free DNA
1. Introduction
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer death with
a five-year survival rate less than 10% [1]. A crucial reason for the poor prognosis is that
many patients are diagnosed with late-stage disease, which unfortunately makes curative
treatment impossible.
Actually, the only clinical available biomarker for PDAC is carbohydrate antigen-19-9
(CA-19-9). CA-19-9 has prognostic properties, as elevated levels are more common in
advanced cancer stages. Further, preoperative increased level of CA-19-9 is associated with
decreased survival and low resectability rate [2,3]. Unfortunately, CA-19-9 lacks sufficient
sensitivity and specificity for use as a diagnostic marker [4,5]. In addition, 10% of the
population lacks the ability to produce CA-19-9 due to Lea-b-blood group status [2,4,6].
It would be a major advance for patients if additional blood-borne biomarkers were
available to facilitate the detection of PDAC at an early stage. A blood-based diagnostic
marker for PDAC would be ideal for screening high-risk individuals or even in patients
with an intermediate risk of developing PDAC, such as patients with chronic pancreatitis,
late-onset diabetes and familiar disposition to PDAC [7]. Such biomarkers could serve
as a supplement to existing clinical tools in the diagnostic work-up of patients suspected
of PDAC. Furthermore, additional prognostic biomarkers would be highly beneficial
by facilitating the initial identification of patients with more aggressive tumor biology,
optimize therapeutic decision making and promote individualized therapy.
The objective of this present paper is to give an update on the current literature on
cell-free DNA methylation as blood-based biomarkers for PDAC.
2. The Importance of Blood-Based Biomarkers for PDAC
Blood-based markers have several advantages over tissue-based markers. The current
standard of care for diagnosing PDAC involves examination of tumor tissue either by fine
needle aspiration cytology or histological examination of biopsies or surgical specimens [8],
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which all are invasive procedures entailing a risk of complications. Blood-based tests are
minimally invasive, involving only limited discomfort, and have no major complications.
They can easily be repeated to enable close monitoring of the disease to evaluate response
to treatment or early detection of recurrence [9–11].
As pancreas, or at least part of it, is difficult to access for any kind of tissue sampling,
it calls for much easier methods as liquid biopsies. In addition, the size of the tumor may
limit the ability to sample tissue adequately, and tissue biopsies may not be an accurate
representation of the tumor due to intra-tumor heterogeneity [11–13]. There can also be
molecular differences between the primary tumor and metastatic lesions, and thus a tissue
biopsy from the primary lesion most likely will not represent the metastatic lesions [12]. In
cases where tumor tissue specimens are unavailable from either the primary tumor or the
metastatic lesions, blood-based markers may represent an alternative or a supplement to
existing tools used in the diagnostic work-up and treatment of PDAC [11–13].
3. Cell-Free DNA
The presence of cell-free DNA in peripheral blood has been known for decades [14].
Cell-free DNA in the serum of patients with cancer was first described in 1977, where it
was shown that patients with cancer had a larger amount of cell-free DNA than healthy
individuals [15]. In 1983, similar results were described for pancreatic disease: PDAC
patients had significantly higher levels of cell-free DNA compared to patients with chronic
or acute pancreatitis [16].
The biology of cell-free DNA remains to some extent unclear. However, the release
of nucleic acids into the blood is thought to be related to the apoptosis and necrosis of
cancer cells or secretion by cancer cells [17]. Furthermore, it has been suggested that a part
of the cell-free DNA may act as micrometastases or originate from circulating tumor cells
undergoing cell death [17].
Tumors are usually heterogenic, with a mixture of different cancer cell clones and
normal cell types, resulting in the release of both tumor-derived and wild-type cell-free
DNA into the blood during tumor progression [14,17]. It is still challenging to differentiate
circulating tumor DNA from circulating non-tumor DNA. This challenge is enhanced
by the fact that several benign conditions also are associated with an increased level of
cell-free DNA due to the shedding of nucleic acids into the blood by apoptotic and necrotic
cells [18,19]. In recent years, free circulating or cell-free DNA have become of major interest
as tools for minimal invasive diagnostics, i.e., “liquid biopsy”. It is an alternative approach
to cancer tissue biopsy for analyzing genetic and epigenetic aberrations.
4. DNA Methylation
DNA methylation consists of the addition of a methyl (CH3) residue to a cytosine
preceding a guanosine, known as a CpG dinucleotide [20–22]. CpG dinucleotides are in
CpG-rich regions known as CpG islands, where the majority of methylated CpG dinu-
cleotides are in repetitive intragenomic sequences. Furthermore, 60% of genes in the human
genome contain one or more CpG islands in the promoter region. However, only 5% of
these promoter sequences are methylated under normal conditions [20–22]. Methylated
DNA results in a tightly packed chromatin structure, and unmethylated DNA is associated
with lightly packed chromatin [20]. Aberrant DNA methylation (hypo- and hypermethyla-
tion) is a fundamental part of carcinogenesis. Global DNA hypomethylation of repetitive
sequences is a part of early carcinogenesis and may lead to chromosomal instability. DNA
hypermethylation often occurs in the CpG islands of the promoter sequences of genes.
Hypermethylation in the promoter regions of tumor suppressor genes result in downreg-
ulation/silencing of tumor suppressor function, whereas hypomethylation in promoter
regions of oncogenes may result in increased gene expression [20,21].
In PDAC aberrant methylation has been shown in precursor lesion of the pancreas [23,24].
A progressive increase in the prevalence of methylation has been demonstrated with
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increasing dysplasia and it has been suggested that specific genes can be target for aberrant
methylation at different stages of pancreatic neoplastic progression [23–25].
5. Cell-Free DNA Methylation as Diagnostic Biomarkers for PDAC
Melnikov et al. (2009) was the first to publish a study on plasma DNA methylation
changes as blood-based diagnostic biomarkers of PDAC. Using microarray analysis, the
promoter region of five genes were detected as hypomethylated in cell-free DNA of PDAC
patients (n = 30), reaching a 76% sensitivity and 59% specificity [26].
Liggett et al. (2010) used the same microarray analysis to identify seventeen gene
promoter regions aberrantly methylated in plasma cell-free DNA when comparing patients
with PDAC (n = 30), chronic pancreatitis (n = 30) and healthy individuals (n = 30). The
gene panel reached a 90.8% sensitivity and a 91.2% specificity for PDAC when compared
to chronic pancreatitis. In addition, a 78% sensitivity and a 81.7% specificity was demon-
strated when differentiating patients with chronic pancreatitis and healthy individuals [27].
However, no further validation of the results has been published.
Park et al. examined in 2012 by methylation specific PCR promoter hypermethylation
of a six gene panel (NPTX2, UCHL1, SARP2, ppENK, p16 and RASSF1A) in plasma cell-
free DNA of PDAC patients (n = 16), patients with chronic pancreatitis (n = 13), and
healthy individuals (n = 29). Hypermethylation of all six genes were found both in plasma
from patients with PDAC and patients with chronic pancreatitis, however the frequency
was higher in cancer patients, although not statistically significant [28]. Afterwards, a
study including 104 PDAC patients, 60 chronic pancreatitis patients, and five patients
with benign gallstone disease focused on the methylation status of NPTX2 [29]. NPTX2
hypermethylation was found in pretreatment plasma from 84% of PDAC patients, 33% of
patients with chronic pancreatitis and none of the patients with benign gallstone disease
(p-value = 0.016).
The methylation status of a panel of five tumor suppressor genes (p16, p14, RASSF1A,
APC and DCC) was evaluated by Kawasaki et al. in 2013 [30]. PDAC patients (n = 47)
were compared to patients with other types of cancer (n = 197). Pretreatment plasma was
analyzed by methylation specific PCR. Hypermethylation of p16 and RASSF1A was de-
tected in 17% and 34% of patients with PDAC, respectively. Similar methylation frequency
of p16 and RASSF1A was seen for patients with several other types of cancer. Except
for hepatocellular carcinoma where 73.3% of patients had hypermethylated RASSF1A.
Hypermethylation of APC, DCC and p14 were also detected in PDAC patients, however
less frequent [30].
In 2013 Joo Mi Yi et al. analyzed cell-free DNA promoter hypermethylation of BNC1
and ADAMTS1 in pretreatment serum from patients with PDAC (n = 42) and healthy
volunteers (n = 26) [31]. The sensitivity was 79% and 48% for BNC1 and ADAMTS1,
respectively. Specificity was 89% for BNC1 and 92% for ADAMTS1. In addition, BNC1 and
ADAMTS1 showed a promising sensitivity of 90% for stage I PDAC [31]. The results were
validated in 39 patients with PDAC and 95 age-matched controls, and the combination of
ADAMTS1 and BNC1 showed a convincing AUC of 0.95 (0.91–0.98) [32]. The panel was
also analyzed in patients with chronic pancreatitis (n = 8). Unfortunately, seven of the
eight patients with chronic pancreatitis were hypermethylated in either of the two genes,
indicating the test fail to differentiate PDAC and chronic pancreatitis [32].
A recent study by Nidhi Singh et al. [33] examined methylation status of four genes
(SPARC, UCHL1, PENK and NPTX2). Cell-free DNA in plasma of patients with PDAC
(n = 61), patients with chronic pancreatitis (n = 22) and healthy controls (n = 21) were
analyzed. To differentiate PDAC and chronic pancreatitis SPARC reached an AUC of 0.76
(0.65–0.87) and a similar performance was seen for early stage PDAC., whereas the other
genes did not reach statistical significance between PDAC and chronic pancreatitis. In
general, the methylation level of all four genes was significantly higher in PDAC patients
compared with the healthy controls [33].
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In 2015 primarily based on a literature review [34], which addressed genes aberrantly
methylated in PDAC, a panel of 28 promoter regions was designed by our group and
examined in both a diagnostic and prognostic biomarker study [35]. The aim was to
evaluate the overall performance of genes previously examined separately as markers
for PDAC. Cell-free DNA promoter hypermethylation in plasma was analyzed in a large
cohort of PDAC patients (n = 95). A clinically relevant control groups of patients with
chronic pancreatitis (n = 97), patient screened for but not having upper gastrointestinal
cancer (n = 27) and patients with acute pancreatitis (n = 59) were included [35]. Based on
a subgroup of eight genes from the panel a diagnostic prediction model (age > 65 years,
BMP3, RASSF1A, BNC1, MESTv2, TFPI2, APC, SFRP1 and SFRP2) for PDAC was developed
reaching an AUC of 0.86 (95% CI 0.81–0.91). Very importantly, the prediction model was
independent of cancer stage. Subsequently, an external validation study of the diagnostic
gene panel has been initiated, and in addition the additive effect of CA-19-9 was analyzed.
So far, the results are promising, especially as the test is developed using patients with
benign pancreatic disease as the control group, which enables differentiation of cancer
specific hypermethylation and hypermethylation in response to an inflammatory pancreatic
reaction, as observed in chronic or acute pancreatitis. This aspect is important because
chronic pancreatitis is a significant risk factor for PDAC and the differentiation of patients
with PDAC from patients with chronic pancreatitis is a known clinical challenge.
Recently other studies combining methylation analyses with other diagnostic modali-
ties has been published. Fujimoto et al. analyzed methylation status of RUNX3 in plasma
cell-free DNA in combination with CA-19-9 in patients with PDAC (n = 55), chronic pan-
creatitis (n = 12) and healthy volunteers (n = 80). RUNX3 methylation had a sensitivity
of 50.9% for PDAC, with a 93.5% specificity using the total control group. By combin-
ing RUNX3 methylation and CA-19-9 the sensitivity increased substantial (85.5%) [36].
Furthermore, Keiko Shinjo and coworkers [37] examined methylation status of five genes
(ADAMTS1, HOXA1, PCDH10, SEMA5A and SPSB4 in serum from patients with PDAC
(n = 47) and healthy controls (n = 14). The mean methylation level of the five genes in
cell-free DNA was not significant different between cancer patients and controls. However,
twenty-three PDAC patients had at least one of the genes methylated leading to a 49%
sensitivity and an 86% specificity. Additionally, KRAS mutation in cell-free DNA was de-
tected in twenty-three PDAC patients. When combining KRAS mutation and methylation
status the diagnostic performance improved (68% sensitivity and 86% specificity) [37]. Both
studies lack validation, which is needed to confirm the results.
Using various methods, which is outside the scope for this present review, the methyla-
tion status of a broad spectrum of genes has been analyzed in cell-free DNA in order to find
genes with potential to work as diagnostic biomarkers for PDAC. Table 1 summarizes the
above-mentioned diagnostic studies. Hypermethylation of several genes has been detected
in plasma and serum from patients with PDAC. At low frequency hypermethylation of the
same genes are also present in plasma and serum from patients with chronic pancreatitis
and healthy controls [27,28,32,35]. In conclusion, cell-free DNA hypermethylation has
the potential to work as diagnostic biomarkers for PDAC. However, none of the genes jet
examined has the potential to function as an individual diagnostic marker and the perfor-
mance of the previously described gene panels do not allow any of them to be used as a
stand-alone test for PDAC diagnosis. Nevertheless, so far, the results from the validation
study of the diagnostic gene panel developed by our group, which is based on hyperme-
thylation of eight genes in combination with CA-19-9 shows a promising performance.
This together with the other studies illustrating improved performance in combination
with KRAS mutation [37] or CA-19-9 [36], indicate a panel of hypermethylated genes in
combination with other diagnostic modalities might be needed to bolster the diagnostic
power, which seems reasonable keeping in mind the molecular heterogenicity of PDAC.
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Table 1. Studies on cell-free DNA methylation in plasma/serum as diagnostic biomarkers for pancreatic adenocarcinoma.
Reference Genes Method Cases Controls Results Strenghts Limitations Maturity Level *
Nidhi Singh





MSP PDAC 61 CP 22HC 21
SPARC: AUC of 0.76 (0.65–0.87)
The other genes did not reach
statistical significance.
- Consecutive inclusion of
PDAC patients.
- Large group of well-defined cases.
- Inclusion of controls with benign
pancreatic disease.
- Lack information on whether cases
and controls were matched according to
age, sex etc.











Sens; 50.9%, Spec; 93.5% (the total
control group)
Combining RUNX3 and CA-19-9:
Sens; 85.5%, Spec; 93,5%
- Large group of cases and controls.
- Inclusion of controls with benign
pancreatic disease.
- Not matched according to age and sex.











qMSP PDAC 47 HC 14
The panel of five genes (with at least one gene
methylated): Sens; 49%, Spec; 86%
Combining the gene panel and KRAS mutation
in cell-free DNA: Sens; 68%, Spec; 86%
- Well described and comprehensive
analysis of tissue samples.
- Pretreatment blood samples.
- Cases and controls matched according
to age and sex.
- Lacking a control group of patients













MSP PDAC 95 CP 97SN 27
Prediction model combining hypermethylation
status of the eight genes and age <65 years:
PDAC vs. CP and SN: AUC 0.86 (0.81–0.91)
- Consecutive inclusion of
PDAC patients.
- Large group of cases and controls with
benign pancreatic disease.
- Pretreatment plasma
- Cases and controls not age-matched.













Combining BNC1 and ADAMTS1:
PDAC vs HC: AUC 0.95 (0.91–0.98)
CP: 7/8 were had either BNC1 or ADAMTS1
methylated.
- Population-based matched and
age-matched controls.
- Pretreatment serum.
- Small control group of CP patients
- Racial difference between cases
and controls.
Phase 1/Phase 2.
Validation study of Joo
Mi Yi et al., 2013 [31].
Joo Mi Yi et al.,
2013 [31]
BNC1
ADAMTS1 MOB PDAC 42 HC 26
BNC1: PDAC 79% (33/42), HC 11,5% (3/26)
ADAMTS1: PDAC 48% (20/42), HC 7.7%
(2/26)
Combining BNC1 and ADAMTS1 did not
improve sensitivity and specificity.
- Well described and comprehensive
analysis of cell-lines and tissue samples.
- Pretreatment serum.
- Lack information on whether cases
and controls were matched according to
age, sex etc.
- Lacking a control group of patients
with benign pancreatic disease
Phase 1 and phase 2.
One validation study is






















- Large cohort of cases.




Park, Ryu et al.,









Statistically significant difference (P = 0.016)
- Pretreatment plasma.
- Large cohort of cases and controls.
- Include controls with benign
pancreatic disease.
- Not age matched cases and controls
- No description of inclusion period.
Phase 1/Phase 2.
A validation study of
NPTX2 (Park, Baek
et al., 2012 [28]).
No further validation.
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Table 1. Cont.
Reference Genes Method Cases Controls Results Strenghts Limitations Maturity Level *








MSP PDAC 16 CP 13HC 29
Frequency of hypermethylation:
NPTX2: PDAC 6/16, CP 2/13, HC 0/29
UCHL1: PDAC 4/16, CP 2/13, HC 0/29
SARP2: PDAC 5/16, CP 3/13, HC 0/29
ppENK: PDAC 5/16, CP 2/13, HC 0/29
P16: PDAC 4/16, CP 2/13, HC 1/29
RASSF1A: PDAC 1/16, CP 1/13, HC 0/29
No statistically significant difference.
- Include controls with benign
pancreatic disease.
- Small cohort of cases and controls.
- No information on treatment before
blood sampling.








2010 [27] MethDet56 PDAC 30
CP 30
HC 30
- 8 gene promoters could differentiate CP
and HC:
Sens; 78.0%, Spec; 81.7%
- 14 gene promoters could differentiate PDAC
and CP:
Sens; 90.8%, Spec; 91.2
- Cases and controls matched on sex,
age and race.
- Detailed description of CP patients.
- Pretreatment plasma.
- No information on whether the
aberrantly methylated genes were hypo-
or hypermethylated.




2009 [26] MethDet56 PDAC 30
CP 30
HC 30
Based on five hypomethylated
promoter regions:
Sens; 76%, Spec; 59%
- Cases and controls matched on sex
and age.
- No description of inclusion period **.




PDAC; Pancreatic ductal adenocarcinoma, CP; Chronic pancreatitis, SN; Patients with symptoms mimicking upper gastrointestinal cancer, but not having cancer, HC; Healthy controls, GD; Gallstone disease;
Sens; Sensitivity. Spec; Specificity; MethDet56; Microarray-mediated methylation analysis of 56 fragments, MSP; Methylation specific PCR, qMSP; Quantitative methylation specific PCR; * Maturity level
according to phases of biomarker development defined by Pepe et al, 2001 [38]. Phase 1: Preclinical explorative studies – is often performed on tumor tissue and non-tumor tissue to identify a promising direction
for a potential useful biomarker. Phase 2: Clinical assay and validation studies—is performed on a non-invasive specimen e.g., plasma or serum to detect an established disease and distinguish cancer subjects
from subjects without cancer. Phase 3: Retrospective longitudinal studies—the biomarker detects disease early before it becomes clinical e.g., clinical specimens collected from cancer subjects before their clinical
diagnosis of cancer are compared to specimens from controls who have not developed cancer. Phase 4: Prospective screening studies—the performance (both the detection rate and the false referral rate) of the
biomarker is identified in a relevant population. Phase 5: Cancer control studies—is to estimate the reduction in cancer mortality afforded by screening with the biomarker. ** Both studies included patients from
the same center, as none of the studies describe the inclusion period, it is impossible to exclude patient overlap.
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The studies of DNA methylation have brought us closer to a diagnostic biomarker
for PDAC, but we are not quite there yet. Many studies are of small sample size and still
lack validation. According to the five-phase structure of biomarker development described
by Pepe et al. [38] studies on DNA methylation as diagnostic biomarkers for PDAC only
reach phase 2 (see Table 1). Currently, no diagnostic biomarker for PDAC based on cell-
free DNA methylation has reach phase 3, which involves a retrospective longitudinal
study of clinical specimens collected from cancer patients before their clinical diagnosis.
In addition, no phase 4 studies (prospective studies) or phase 5 studies, which estimate
the reduction of cancer mortality afforded by the biomarker, do exist. In general, further
research is needed. Well-designed validation studies, including both patients with benign
and malignant pancreatic disease (etc. patients with late-onset diabetes and individuals
with a familiar disposition to PDAC) testing broad gene-panels in combination with other
diagnostic modalities will hopefully get closer to a clinical useful diagnostic marker.
6. Cell-Free DNA Methylation as Prognostic Biomarkers for PDAC
As mentioned earlier a progressive increase in aberrant DNA methylation, both hyper-
and hypomethylation, has been demonstrated with increasing dysplasia [23,24], indicating
there to be a prognostic potential in DNA methylation changes.
In general, only very few studies on the prognostic value of hypermethylated cell-free
DNA in PDAC do exist. In 2017 our group investigated cell-free DNA in PDAC regard to
stage classification and survival [25,39].
6.1. Number of Hypermethylated Genes According to Cancer Stage and Survival
Similar to other studies, a study by our group demonstrated that hypermethylated cell-
free DNA is detectable in all stages of PDAC [25,35,39]. Furthermore, the study discovered
that patients with distant metastases had an even higher number of hypermethylated genes
in cell-free DNA compared with patients with localized disease [25]. Distant metastasis has
previously been reported to result in a larger amount of cell-free DNA [10]. However, the
level of cell-free DNA was not associated with cancer stage in our study [25]. The study
of Park et al. [28] was not able to show similar association between metastatic PDAC and
a higher number of hypermethylated genes in cell-free DNA, which could be due to a
lack of power or differences in genes analyzed. However, our results on cell-free DNA
are consistent with a study on PDAC tumor tissue [23]. These observations suggest that
hypermethylated promoter regions accumulate during the course of PDAC development
and progression.
Another study by our group demonstrated that the number of hypermethylated
genes in cell-free DNA was associated with survival. Patients with more than ten hy-
permethylated genes were more likely to die during the first year after diagnosis than
patients with fewer hypermethylated genes [39]. Similar association between number of
hypermethylated genes and poor survival has been reported for head and neck cancer [40].
6.2. Methylated Genes Associated with Distant Metastasis
Cell-free DNA hypermethylation of seven individual genes ALX4, BNC1, HIC1,
SEPT9v2, SST, TFPI2, and TAC1 has been associated with distant metastasis in a study
by our group [25]. Likewise, HIC1 hypermethylation in tumor tissue has previously been
detected in PDAC stage III-IV [41]. In addition, Park et al. described cell-free DNA
hypermethylation of NPTX2 to increase significantly with aggravating tumor stage [28].
Nidhi Singh and coworkers [33] also found cell-free DNA hypermethylation of NPTX2 and
SPARC to be more pronounced in stage IV PDAC. Similar prognostic value of NPTX2 was
not found in our study.
6.3. Methylated Genes According to Cancer Stage
To enable differentiation of PDAC patients according to cancer stage two prediction
models were developed by our group [25]. A panel based on the hypermethylation status of
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eight genes (SEPT9v2, SST, ALX4, CDKN2B, HIC1, MLH1, NEUROG1, and BNC1) enabled
with high performance (AUC of 0.87) the distinction of stage IV PDAC patients from
PDAC patients with stage I-III. Another panel (MLH1, SEPT9v2, BNC1, ALX4, CDKN2B,
NEUROG1, WNT5A, and TFPI2) enabled the differentiation of potentially resectable disease
(stage I and II) from non-resectable disease (stage III and IV) (AUC of 0.82) [25].
6.4. Methylated Genes According to Survival
Furthermore, the association between cell-free DNA hypermethylation and survival of
PDAC patients was investigated by our group [39]. Overall, promoter hypermethylation had
a negative impact on survival. However, hypermethylation of a few specific genes had a
positive effect on survival. Hypermethylation of SFRP1, BMP3, and TFPI2 was significantly
associated with impaired survival in stage IV disease [39]. In concordance with our findings,
hypermethylation of SFRP1 in tumor tissue has been identified as an independent risk factor for
poor overall survival in breast cancer [42] and renal cancer [43]. In addition, hypermethylation
of TFPI2 in hepatocellular carcinoma tumor tissue is associated with advanced cancer stage
and shorter survival [44], similar to our results for cell-free DNA in PDAC.
Based on hypermethylated cell-free DNA prediction models for survival of patients
with PDAC were developed [39], which enabled the stratification of patients in risk groups
according to survival. The results indicate a biological variation within pancreatic ade-
nocarcinoma that influences patient outcome. These findings are consistent with a study
of PDAC tissue [45] describing a methylation signature associated with short survival
time and another methylation signature associated with long survival time. Likewise,
Minqi Gu et al. [46] identified a four-gene methylation signature (CCNT1, ITGB3, SDS
and HMOX2) in tumor tissue to predict the prognosis of PDAC patients. Based on the
methylation signature patients were divided into a high-risk and a low-risk group [46].
These results indicate that DNA hypermethylation has the potential to provide prognostic
information in addition to the TNM classification, which clearly would benefit patients
and clinicians’ therapeutic decisions and facilitate the correct choice of treatment.
No doubt, cell-free DNA methylation has prognostic potential as blood-based biomark-
ers. Nevertheless, the studies in the area are few and validation of the results are lacking.
An external validation of the prognostic biomarker studies by our group has just been initi-
ated. Unfortunately, it is still too early to say anything about the outcome. Further research
is needed, as well as well-designed prospective studies tracking the methylation profile in
cell-free DNA of PDAC patients according to prognosis, treatment and recurrence are.
7. Conclusions
The current literature discussed above, clearly indicates that cell-free DNA methyla-
tion has the potential to be the fundament of useful blood-based diagnostic and prognostic
biomarkers for PDAC, however further research is still needed before clinical application
(Table 2).
Table 2. Summary of Recommended Future Directions for the Field.
• Cases and controls matched according to age, sex and race.
• The use of pretreatment blood samples.
• Studies combining methylated gene-panels and other diagnostic modalities.
• Large validation studies including cases with early stage cancer and controls with benign
pancreatic disease.
• Validation on cases with pancreatic cancer precursor lesions.
• Validation on cases with increased risk of pancreatic cancer e.g., subjects with a risk of familial
pancreatic cancer and subjects with diabetes.
• Retrospective longitudinal studies.
• Prospective screening studies of subjects with increased risk of pancreatic cancer.
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ADAMTS1 A disintegrin and metalloproteinase with thrombospondin motifs 1
APC Adenomatous polyposis coli
ALX4 Homebox Protein Aristaless-Like 4
BNC1 Basonuclin 1
BMP3 Bone Morphogenetic Protein 3
CCNT1 Cyclin T1
CDKN2A Cycklin-Dependent Kinase Inhibitor 2A (p16)
CDKN2B Cycklin-Dependent Kinase Inhibitor 2B (p15)
DCC Deleted in Colorectal Carcinoma
HMOX2 Heme Oxygenase 2
HOXA1 Homeobox protein Hox A1
HIC1 Hypermethylated in Cancer 1
ITGB3 Integrin beta-3
MESTv2 Mesoderm Specific Transcript 2
MLH1 MutL Homolog 1
NEUROG1 Neurogenin 1
NPTX2 Neuronal pentraxin 2
ppENK Preproenkephalin
PCDH10 Protocadherin 10
RASSF1A Rras associated domain family member 1
RUNX3 Runt-related transcription factor 3
SARP1 Secreted apoptose related protein 1
SARP2 Secreted apoptose related protein 2
SPARC Secreted Protein Acidic and Cysteine Rich (SPARC)
SEMA5A Semaphorin 5A
SEPT9v2 Septin 9 Transcript Variant 2
SDS Serine Dehydratase
SST Somatostatin
SPSB4 SplA/Ryanodine Receptor Domain and SOCS Box Containing 4
TAC1 Tachykinin Precusor 1
TFPI2 Tissue factor pathway inhibitor 2
UCHL1 Ubiquitin carboxy-terminal hydrolase L1
WNT5A Wingless-Type MMTV Integration Site Family, Member 5A
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